{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:17:35Z","timestamp":1767665855991,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.pnpbp.2021.110470","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T23:38:33Z","timestamp":1635896313000},"page":"110470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Switching from blonanserin oral tablets\/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study"],"prefix":"10.1016","volume":"113","author":[{"given":"Kazutaka","family":"Ohi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Takai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Kuramitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Shioiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2021.110470_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia","volume":"24","author":"Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0010","first-page":"Fc07","article-title":"Clinical assessment of weight gain with atypical antipsychotics - blonanserin vs amisulpride","volume":"9","author":"Deepak","year":"2015","journal-title":"J. Clin. Diagn. Res. JCDR"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0015","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/0269881112447988","article-title":"Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?","volume":"26","author":"Desmarais","year":"2012","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0020","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/npr2.12057","article-title":"Blonanserin versus haloperidol in Japanese patients with schizophrenia: a phase 3, 8-week, double-blind, multicenter, randomized controlled study","volume":"39","author":"Harvey","year":"2019","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/NDT.S59861","article-title":"Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone","volume":"10","author":"Hori","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/pcn.12275","article-title":"Psychotropic dose equivalence in Japan","volume":"69","author":"Inada","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0040","first-page":"39","article-title":"Extrapyramidal symptom profiles assessed with the drug-induced extrapyramidal symptom scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol","volume":"18","author":"Inada","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jphs.2020.09.006","article-title":"Safety and effectiveness of oral blonanserin for schizophrenia: a review of Japanese post-marketing surveillances","volume":"145","author":"Inoue","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2045125312458311","article-title":"Transdermal patches: the emerging mode of drug delivery system in psychiatry","volume":"2","author":"Isaac","year":"2012","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2019.07.055","article-title":"Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: a 6-week randomized, double-blind, placebo-controlled, multicenter study","volume":"215","author":"Iwata","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40263-019-00692-6","article-title":"Long-term safety and efficacy of blonanserin transdermal patches in Japanese patients with schizophrenia: a 52-week open-label, multicenter study","volume":"34","author":"Iwata","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/a-0574-0088","article-title":"Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Kishi","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0075","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jpsychires.2021.04.032","article-title":"Efficacy and safety of antipsychotic treatments for schizophrenia: a systematic review and network meta-analysis of randomized trials in Japan","volume":"138","author":"Kishi","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0080","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/jcph.1835","article-title":"Pharmacokinetic evaluation of blonanserin transdermal patch: population analysis and simulation of plasma concentration and dopamine D(2) receptor occupancy in clinical settings","volume":"61","author":"Kitamura","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0085","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpsychires.2015.07.015","article-title":"Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double-blind, parallel-group multicenter randomized trial","volume":"69","author":"Li","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0090","first-page":"2241","article-title":"Long-term clinical study of blonanserin for schizophrenia - a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group)","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0095","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ijnp\/pyaa071","article-title":"Striatal dopamine D2 receptor occupancy induced by daily application of blonanserin transdermal patches: phase II study in Japanese patients with schizophrenia","volume":"24","author":"Nishibe","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pnpbp.2010.08.030","article-title":"Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia","volume":"35","author":"Ogino","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110470_bb0105","article-title":"Safety and efficacy in randomized controlled trials of second-generation antipsychotics versus placebo for cognitive impairments in schizophrenia: a meta-analysis","author":"Ohi","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.dmpk.2020.03.006","volume":"35","author":"Tomita","year":"2020","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2021.110470_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","article-title":"Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial","volume":"33","author":"Yang","year":"2010","journal-title":"Clin. Neuropharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621002293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621002293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:00:51Z","timestamp":1759521651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584621002293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":23,"alternative-id":["S0278584621002293"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110470","relation":{},"ISSN":["0278-5846"],"issn-type":[{"type":"print","value":"0278-5846"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from blonanserin oral tablets\/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110470"}}